OMB APPROVAL
---------------------------
UNITED STATES OMB Number: 3235-0145
SECURITIES AND EXCHANGE COMMISSION Expires: October 31, 1994
Washington, D.C. 20549 Estimated average burden
hours per response ... 14.90
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 4)
BOSTON LIFE SCIENCES, INC.
(Formerly Known as Greenwich Pharmaceuticals Incorporated)
- -------------------------------------------------------------------------------]
(Name of Issuer)
Common Stock, par value $.01 per share
- -------------------------------------------------------------------------------
(Title of Class of Securities)
397003 10 4
---------------------------------------------------
(CUSIP Number)
Check the following box if a fee is being paid with this statement [ ]. (A fee
is not required only if the reporting person: (1) has a previous statement on
file reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Page 1 of 8 pages
<PAGE>
3100 Schedule 13G
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
CUSIP No. 397003-10-4 13G Page 2 of 8 Pages
----------- ------ -------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
ORTELIUS TRADING L.P.; 13-3512778
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
- -------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER 0
SHARES ----------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY ----------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER 0
REPORTING ----------------------------------------------------------------
PERSON WITH 8 SHARED DISPOSITIVE POWER
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON 0 shares of Common Stock
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES*
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
0
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
BD
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
3100 Schedule 13G
- -------------------------------------------------------------------------------
- -------------------------------------------------------------------------------
CUSIP No. 397003-10-4 13G Page 3 of 8 Pages(3)
----------- ------ -------
- -------------------------------------------------------------------------------
1 NAME OF REPORTING PERSONS
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GDK, Inc.; NA
- -------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ]
(b) [ ]
- -------------------------------------------------------------------------------
3 SEC USE ONLY
- -------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
British Virgin Islands
- -------------------------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER 5,847,000
SHARES ----------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY ----------------------------------------------------------------
EACH 7 SOLE DISPOSITIVE POWER 5,847,000
REPORTING ----------------------------------------------------------------
PERSON WITH 8 SHARED DISPOSITIVE POWER
- -------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING
PERSON 5,847,000 shares of Common Stock
- -------------------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES*
- -------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
14.3%
- -------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
BD
- -------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
<PAGE>
Item 1(a). Name of Issuer:
Boston Life Sciences, Inc.
(formerly known as Greenwich Pharmaceuticals Incorporated)
Item 1(b). Address of Issuer's Principal Executive Offices:
501 Office Center Drive
Fort Washington, Pennsylvania 19034
Item 2(a). Name of Person Filing:
This Amendment 4 to Form 13G is being filed by (i) GDK, Inc., a corporation
formed under the laws of the British Virgin Islands ("GDK") with respect to
shares of common stock of the issuer (the "Common Stock") beneficially owned by
it as of December 31, 1995, and (ii) Ortelius Trading L.P., a Delaware limited
partnership ("Ortelius").
As of December 31, 1995, Ortelius no longer beneficially owned any shares
of Common Stock.
Pursuant to Rule 13d-3(d)(1), the aggregate number of shares of Common
Stock beneficially owned by GDK as of December 31, 1995, is 5,847,000. This
total is comprised of the shares underlying 3,898,000 warrants, each of which is
exercisable at the discretion of GDK at any time between now and April 30, 1996,
for 1.5 shares of Common Stock per warrant. Caxton Corporation, a Delaware
corporation ("Caxton"), is GDK's trading advisor. Subject to termination of its
contractual relationship with GDK by a vote of its Board of Directors, Caxton
acts on behalf of GDK as its trading advisor. In such capacity, Caxton directs
GDK's securities investments and is vested with authority over the voting and
disposition of the shares of Common Stock.
Item 2(b). Address of Principal Business Office, or, if None,
Residence.
The address of the principal office of Ortelius Trading L.P. is 667 Madison
Avenue, 10th floor, New York, New York 10021. The address of the principal
office of GDK, Inc. is c/o its Manager, Leeds Management Limited, 129 Front
Street, Penthouse, Hamilton HM12 Bermuda.
Item 2(c). Citizenship: NA
Item 2(d). Title of Class of Securities: Common Stock, par value
$.10 per share
Page 4 of 8 pages
<PAGE>
Item 2(e). CUSIP Number: 397003 10 4
Item 3. The reporting persons originally filed as a group, in accordance with
Rule 13d-1(b)(1)(ii)(H). Each of the reporting persons is a broker or dealer
registered under Section 15 of the Securities Exchange Act of 1934. Subsequent
to the disposition of the Common Stock beneficially owned by Ortelius, Ortelius
filed Form BDW in order to withdraw its broker-dealer registration.
Item 4. Ownership.
(a) Amount beneficially owned: The amount of securities beneficially owned
by GDK as of December 31, 1995, is 5,847,000, consisting, pursuant to Rule
13d-3(d)(1), of 3,898,000 warrants currently exercisable for a total of
5,847,000 shares of Common Stock. The amount of securities beneficially owned by
Ortelius as of December 31, 1995, is zero.
As of October 25, 1995, Ortelius transferred to GDK warrants to purchase
2,923,500 shares of Common Stock for a nominal consideration of $100.00. The
exercise price of the warrants was on said date, and remains, substantially in
excess of the market price of the Common Stock.
(b) Percent of class: As of December 31, 1995, Ortelius beneficially owned
0.0% of the class of Common Stock. Since October 25, 1995 and as of December 31,
1995, GDK beneficially owned 14.3% of the class of Common Stock.
(c) Number of shares as to which Ortelius has:
(i) Sole power to vote or to direct the vote 0
(ii) Shared power to vote or to direct the vote 0
(iii) Sole power to dispose or to direct the
disposition of 0
(iv) Shared power to dispose or to direct the
disposition of 0
Number of shares as to which GDK has: (i) Sole power to vote or to
direct the vote 5,847,000 (ii) Shared power to vote or to direct the
vote 0 (iii) Sole power to dispose or to direct the disposition of
5,847,000 (iv) Shared power to dispose or to direct the disposition of
0
Item 5. Ownership of Five Percent or Less of a Class. Ortelius
has ceased to be the beneficial owner of more than five percent
of the Common Stock.
Page 5 of 8 pages
<PAGE>
Item 6. Ownership of More than Five Percent on Behalf of Another
Person. NA
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Reported on by the Parent Holding Company.
NA
Item 8. Identification and Classification of Members of the
Group. NA
Item 9. Notice of Dissolution of Group. NA
Item 10. Certification.
By signing below, each of the reporting persons hereby certifies that, to
the best of its knowledge and belief, the securities referred to above were
acquired in the ordinary course of business and were not acquired for the
purpose of and do not have the effect of changing or influencing the control of
the issuer of such securities and were not acquired in connection with or as a
participant in any transaction having such purpose or effect.
Page 6 of 8 pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of the undersigned's knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete, and correct.
February , 1996
- ---------------------
Date
GDK, INC.
By:________________________
Maxwell Quin
Secretary
By:________________________
Nitin Aggarwal
President
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of the undersigned's knowledge and
belief, the undersigned certifies that the information set forth in this
statement is true, complete, and correct.
February , 1996
- -------------------
Date
ORTELIUS TRADING L.P.
By: Caxton Corporation
By:________________________
Peter D'Angelo
President
Page 7 of 8 pages
